Close Menu

Geneart

In Brief This Week is a column containing news items that our readers may have missed during the week.

The firm, which now majority-owned by Life Technologies, also posted a sharp gain in its earnings before interest and taxes.

Life Tech now owns 74 percent of the synthetic gene company.

Life Technologies has made a tender offer to acquire the remaining shares of Geneart that it does not already own for around €25.5 million. The total purchase price was approximately €56 million.

The agreement gives Applied Biosystems Deutschland approximately 58 percent of GeneArt's shares.

A proposed HHS guidance for synthetic biology roughly fits a harmonization effort started by the International Gene Synthesis Consortium.

Five firms have formed the International Gene Synthesis Consortium to set gene and customer screening protocols that address security concerns.

The firm's sales increased despite the expiration of an NIH contract.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.